Yuhan Corporation
000100
Rank in Stocks
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Share Price
$63.22
Market Cap
$4.27B
Change (1 day)
-3.12%
Change (1 year)
-23.57%
Country
KR
Trade Yuhan Corporation (000100)
Category
Healthcare
Revenue for Yuhan Corporation (000100)
Revenue in Jun 2026 TTM: $1.72B
According to Yuhan Corporation latest financial reports the company's current revenue (TTM) is $1.72B. In 2024 the company made a revenue of $1.41B a decrease compared to the revenue in the year 2023 that was $1.44B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Yuhan Corporation from 2007 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.72B | 13.61% |
| 2025 | $1.51B | 7.62% |
| 2024 | $1.41B | -2.06% |
| 2023 | $1.44B | 2.04% |
| 2022 | $1.41B | -0.87% |
| 2021 | $1.42B | -4.85% |
| 2020 | $1.49B | 16.39% |
| 2019 | $1.28B | -6.01% |
| 2018 | $1.36B | -0.59% |
| 2017 | $1.37B | 25.25% |
| 2016 | $1.10B | 14.05% |
| 2015 | $960.45M | 3.29% |
| 2014 | $929.82M | 3.74% |
| 2013 | $896.29M | 22.88% |
| 2012 | $729.40M | 24.46% |
| 2011 | $586.04M | -0.96% |
| 2010 | $591.75M | 6.18% |
| 2009 | $557.33M | 17.68% |
| 2008 | $473.59M | -10.14% |
| 2007 | $527.01M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $23.54B | 1,268.60% |
DE
|
|
| $23.73B | 1,280.21% |
DE
|
|
| $29.24B | 1,600.31% |
JP
|
|
| $5.85B | 240.11% |
CH
|
|
| $6.34B | 268.81% |
IN
|
